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Abstract
Background: Clinical studies of osteoarthritis (OA) suggest central sensitization may contribute to the chronic pain
experienced. This preclinical study used the monosodium iodoacetate (MIA) model of OA joint pain to investigate
the potential contribution of spinal sensitization, in particular spinal glial cell activation, to pain behaviour in this
model. Experimental OA was induced in the rat by the intra-articular injection of MIA and pain behaviour (change
in weight bearing and distal allodynia) was assessed. Spinal cord microglia (Iba1 staining) and astrocyte (GFAP
immunofluorescence) activation were measured at 7, 14 and 28 days post MIA-treatment. The effects of two
known inhibitors of glial activation, nimesulide and minocycline, on pain behaviour and activation of microglia and
astrocytes were assessed.
Results: Seven days following intra-articular injection of MIA, microglia in the ipsilateral spinal cord were activated (p <
0.05, compared to contralateral levels and compared to saline controls). Levels of activated microglia were significantly
elevated at day 14 and 21 post MIA-injection. At day 28, microglia activation was significantly correlated with distal
allodynia (p < 0.05). Ipsilateral spinal GFAP immunofluorescence was significantly (p < 0.01) increased at day 28, but not
at earlier timepoints, in the MIA model, compared to saline controls. Repeated oral dosing (days 14-20) with nimesulide
attenuated pain behaviour and the activation of microglia in the ipsilateral spinal cord at day 21. This dosing regimen
also significantly attenuated distal allodynia (p < 0.001) and numbers of activated microglia (p < 0.05) and GFAP
immunofluorescence (p < 0.001) one week later in MIA-treated rats, compared to vehicle-treated rats. Repeated
administration of minocycline also significantly attenuated pain behaviour and reduced the number of activated
microglia and decreased GFAP immunofluorescence in ipsilateral spinal cord of MIA treated rats.
Conclusions: Here we provide evidence for a contribution of spinal glial cells to pain behaviour, in particular distal
allodynia, in this model of osteoarthritic pain. Our data suggest there is a potential role of glial cells in the central
sensitization associated with OA, which may provide a novel analgesic target for the treatment of OA pain.
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Background
Osteoarthritis (OA) is the most prevalent joint disease
and knee OA is the major cause of lower limb disability
in older people worldwide [1]. The major symptoms of
OA are chronic pain and disability. Current analgesic
strategies for the long term treatment of OA pain have
modest effects and are often associated with severe side-
effects. The improved treatment of OA pain is a major
unmet clinical need, which can only be addressed by a
better understanding of the mechanisms that drive this
chronic pain state. Although the structural changes that
occur at the level of the OA joint are well characterized,
the association(s) between these changes and the extent
of pain experienced are ill-defined [2]. This variable link
between injury and pain seen in OA patients, and the
report of spreading pain and facilitation of pain
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responses (known as central sensitization) in OA
patients [3], suggests the spinal and supraspinal [4] pro-
cessing of painful inputs is altered in OA.
The aim of the present study was to investigate the
cellular substrates activated in the spinal cord, a key
region of pain processing and central sensitization, in an
established animal model of OA pain. Intra-articular
injection of the glycolysis inhibitor monosodium iodoa-
cetate (MIA) into the rat knee produces pathology of
the joint [5-8], which has similarities to that seen in
human osteoarthritic joints, and also elicits pain beha-
viours. MIA-treated rats exhibit significant decreases in
weight-bearing on the ipsilateral hind-limb [5,6] and
aberrant pain responses from sites distal to the joint
(secondary hyperalgesia), specifically mechanical allody-
nia of the ipsilateral hindpaw [6,9]. Previous work from
our group has shown that the effects of MIA treatment
on cartilage and subchondral bone pathology are signifi-
cantly correlated with pain behaviour and innocuous
mechanically-evoked responses of spinal neurones at 28
days post-injection, but not at earlier timepoints [10].
The presence of distal mechanical allodynia following
joint pathology [6,9,11] and enhanced spinal neuronal
activity [10] suggests mechanisms of central sensitization
[12], which contribute to other chronic pain states, may
be involved. Central sensitization of nociceptive proces-
sing has been investigated widely [see references in
[12]]. The increased excitability observed in the dorsal
horn that characterises central sensitization results from
specific patterns of nociceptive input from the periphery,
alterations in the dorsal horn and also increased facilita-
tory drive from the brainstem [13]. The establishment of
central sensitization leads to tactile allodynia and the
“spread” of pain hypersensitivity to healthy tissue (sec-
ondary hyperalgesia). Traditionally the establishment of
central sensitization was considered a purely neuronal
event. This notion was dispelled by the demonstration
of a significant role for non-neuronal, glial, cells of dif-
ferent types in the establishment and maintenance of
central sensitization particularly in neuropathic pain
states [14-16]. Activation of spinal glial cells has a pivo-
tal role in the generation and maintenance of allodynia
following nerve injury [see references in [12,14-19]. In
this regard, the commonality of OA pain mechanisms
with neuropathic pain states is of particular note [20].
Spinal microglia [21], but not astrocytic, activation has
been reported at early timepoints in the MIA model of
OA pain and was associated with pain behaviour [22].
However, it is only at later time-points (day 28) that
neuronal correlates of pain behaviour are observed in
this model of OA pain [10]. We hypothesised that distal
allodynia associated with pathological changes to the
knee following MIA treatment would be associated with
changes in the activation state of both microglia and
astrocytes, which are also increasingly implicated in
maintaining chronic pain states [23], at this later time-
point.
The aim of the present study was to correlate changes
in microglial activation state alongside potential changes
in astrocytic reactivity both at early and late time-points
in this model. The functional contribution of microglia
and astrocytes to the development of chronic pain beha-
viour was assessed by determining the effects of the tet-
racycline minocycline, which attenuates microglia
activation and chronic pain behaviour [19], and the
cycloxygenase inhibitor nimesulide, on pain behaviour
and activation of glial cells in the spinal cord in this
model of OA pain.
Results
Spinal glial cell activation is significantly correlated with
OA pain behaviour
As previously described, intra-articular injection of MIA
significantly (p < 0.001) decreased ipsilateral weight-
bearing and mechanical withdrawal thresholds of the
hindpaw (distal allodynia), compared to saline-treated
rats, from post-injection day 7 onwards (Additional file
1, Figure S1). Numbers of Iba-1 positive, morphologi-
cally identified, activated microglia were significantly
increased in the ipsilateral spinal cord at days 7, 14 and
28 in MIA-treated rats (Figure 1A), compared to the
contralateral side. There was also a significant (p <
0.001) difference in the numbers of Iba-1 positive, mor-
phologically identified as activated, microglia in the ipsi-
lateral spinal cord of MIA-treated rats, compared to
saline-treated rats, at both days 14 and 28 (Figure 1B,
Additional file 2, Figure S2A). The numbers of activated
microglia in the ipsilateral spinal cord was significantly
correlated with distal allodynia at Day 28 (p < 0.05, 2-
tailed Spearman’s rank correlation, Spearman R = -0.71),
but not at earlier time points (2-tailed Spearman’s Rank
correlation; Day 7: Spearman R = -0.11; Day 14: Spear-
man R = -0.35).
The potential activation of spinal astrocytes was also
investigated in the MIA model. Increases in GFAP
immunofluorescence, indicative of astrocyte activation,
were only observed at day 28 in MIA-treated rats.
GFAP immunofluorescence was significantly increased
in the ipsilateral dorsal horn of MIA-treated rats, com-
pared to the contralateral spinal cord and the ipsilateral
spinal cord of saline-treated rats at this timepoint (Fig-
ure 2, Additional file 2, Figure S2B). At this timepoint,
GFAP immunofluorescence in the ipsilateral dorsal horn
of the spinal cord was significantly correlated with distal
allodynia (p < 0.01, 2-tailed Spearman’s rank correlation,
Spearman R = -0.84). To provide further supportive evi-
dence for the activation of astrocytes in this model of
OA pain, expression of GFAP mRNA in the spinal cord
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of MIA-treated was also studied. GFAP mRNA was ele-
vated in the ipsilateral and contralateral spinal cord in
MIA-treated rats, compared to saline-treated rats at day
28. Although the magnitude of elevation of GFAP
mRNA was comparable in the ipsilateral and contralat-
eral spinal cord of MIA-treated rats, compared to saline
controls, significance was only reached for the contralat-
eral spinal cord (Additional file 3, Figure S3). These
data suggest there may be bilateral changes in GFAP
reactivity at later time points in this model.
Inhibition of spinal glial cell activation has sustained
inhibitory effects on OA pain behaviour
Oral administration of nimesulide (days 14-20 post-
MIA injection) significantly attenuated MIA-induced
decreases in weight bearing (Figure 3) and distal allo-
dynia (Figure 4) in MIA-treated rats, compared to
MIA-treated rats receiving vehicle, throughout the per-
iod of drug administration. At day 21, just after dosing
with nimesulide had ceased, the number of Iba-1 posi-
tive activated microglia in the ipsilateral dorsal horn of
nimesulide-treated MIA rats was significantly lower
than the number present in MIA-treated rats which
received vehicle (Figure 5A). Consistent with the time-
course of astrocyte activation described above, GFAP
immunofluorescence was not significantly altered in
the ipsilateral spinal cord of MIA-treated rats at day
21, compared to both contralateral spinal cord and sal-
ine controls. Repeated daily treatment with nimesulide
did not alter GFAP immunofluorescence of the
Figure 1 Timecourse of spinal microglia activation in MIA-treated rats. (A) Positively identified spinal microglia were increased in the
ipsilateral spinal cord of MIA-treated rats at days 7, 14 and 28, when compared to the contralateral spinal cord. Typical dorsal sections taken
from spinal cords of MIA treated rats at days 7, 14 and 28 post- injection. (B) Quantification of positively identified activated microglia at the
different timepoints in both treatment groups reveals significant differences. Data are expressed as mean % of the number of activated
microglial in contralateral dorsal horn (100% baseline). Statistical comparison between number of Iba-1 positive cells in ipsilateral versus
contralateral spinal cord were performed using a one-way ANOVA with a Dunnett’s multiple comparison test *p < 0.05, **p < 0.01, ***p < 0.001.
For comparisons between treatment groups, MIA versus saline-treated rats, a Kruskall Wallis test with a Dunn’s post hoc test was used. **p <
0.01, ***p < 0.001.
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ipsilateral spinal cord of MIA-treated rats at day 21
(Figure 5B).
Once dosing with nimesulide had ceased, changes in
weight bearing returned to pre-nimesulide values in
MIA treated rats from day 21 onwards (Figure 3). By
contrast, the inhibitory effects of nimesulide on distal
allodynia persisted even once dosing had ceased and
these inhibitory effects were maintained from day 21
until the end of the study (day 28) (Figure 4). Since
nimesulide treatment has sustained inhibitory effects on
distal allodynia in MIA-treated rats, we then investigated
the potential longer-term effects of repeated daily treat-
ment (days 14-20) with nimesulide on microglia and
astrocyte activation at day 28 in MIA-treated rats. In
this case, the earlier treatment with nimesulide
significantly decreased the number of Iba-1 positive acti-
vated microglia (Figure 5A) and the level of GFAP
immunofluorescence (Figure 5B) in the ipsilateral spinal
cord at day 28 of MIA-treated rats, compared to MIA-
treated rats receiving vehicle. Nimesulide treatment did
not alter MIA-induced joint pathology at day 28 (data
not shown).
To further confirm the association between pain beha-
viour and spinal glial activation in this model of OA
pain, we determined the effects of another inhibitor of
glial cell activation, minocycline, on pain behaviour and
glial cell activation. Minocycline treatment (30 mg.kg-1)
significantly (P < 0.01) attenuated pain behaviour
(mechanical withdrawal thresholds: MIA plus vehicle: 4
+/- 1.25 grams; MIA plus minocycline 13.75 +/- 1.41
Figure 2 Timecourse of spinal astrocyte activation in MIA-treated rats. A: GFAP immunofluorescence, as a marker of astrocytes, was
increased in the ipsilateral spinal cord of MIA-treated rats at day 28 post MIA treatment, compared to the contralateral spinal cord. B: Data are
expressed as mean grey intensity of spinal GFAP immunofluorescence in ipsilateral and contralateral dorsal horn. Statistical comparison between
GFAP immunofluorescence in ipsilateral versus contralateral spinal cord were performed using a two-way ANOVA with a Bonferroni post hoc
test: **p < 0.01, ***p < 0.001.
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Figure 3 Nimesulide attenuates established weight bearing deficits in MIA-treated rats. A: Timecourse of the effects of repeated oral
administration of nimesulide (10 mg.kg-1; days 14-20) on weight bearing on the ipsilateral hindpaw in MIA and saline-treated rats. Arrows
indicate the timing of drug administration. B: Histograms comparing the effects of repeated oral administration of nimesulide before (day 14),
during (day 18) and after (day 21 and 28) drug administration. Data are expressed as mean ± SEM. Statistical analyses were performed using a
Kruskall-Wallis test with a Dunn’s post-hoc test: *p < 0.05, **p < 0.01.
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Figure 4 Nimesulide attenuates established allodynia in MIA-treated rats. A: Timecourse of the effects of repeated oral administration of
nimesulide (10 mg.kg-1; days 14-20) or vehicle on mechanical withdrawal thresholds of the ipsilateral hindpaw in MIA and saline-treated rats.
Arrows indicate the timing of drug administration. B: Histograms comparing the effects of repeated oral administration of nimesulide before (day
14), during (day 18) and after (day 21 and 28) drug administration. Data are expressed as mean ± SEM. Statistical analyses were performed using
a Kruskall-Wallis test with a Dunn’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
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grams) and the number of Iba-1 positive activated
microglia in the ipsilateral dorsal horn of MIA-treated
rats, compared to the effect of vehicle, at day 28 (Figure
6A). Furthermore, minocycline treatment significantly
reduced the MIA-induced increase in GFAP immuno-
fluorescence in the ipsilateral spinal cord of MIA treated
rats, compared to the effect of vehicle at day 28 (Figure
6B).
Discussion
Here we demonstrate that the MIA model of OA pain is
associated with a time dependent activation of microglia
and, for the first time, the later activation of astrocytes
in the spinal cord. The timecourse of activation of astro-
cytes was slower, compared to microglia, and significant
changes in ipsilateral GFAP immunofluorescence were
only observed at day 28 post-MIA injection. As pre-
viously described [10] intra-articular injection of MIA
was associated with significant changes in weight bear-
ing and decreases in hindpaw mechanical withdrawal
thresholds, indicative of distal allodynia. Significant
levels of distal allodynia and increases in the number of
activated microglia in the ipsilateral spinal cord of MIA-
treated rats were observed at day 7 post-MIA injection.
In keeping with two recent studies [21,22], the numbers
of activated microglia present in the ipsilateral spinal
cord were further increased at day 14, and in our hands
by day 28 the numbers of activated microglia were
declining.
The present study used intra-articular injection of
MIA as a model of joint pathology and pain associated
with OA. The dose of MIA employed has previously
been shown to produce joint pathology which has fea-
tures consistent with that seen in patients with endstage
OA. Importantly, this model of OA pain is associated
with changes in weight bearing and distal (hindpaw)
allodynia and, therefore, has translational relevance to
both pain on load-bearing and referred pain, both of
which are experienced by OA sufferers. Although pain
behaviour is apparent at early timepoints in the MIA
model, we have shown that it is only at later timepoints
(day 28 post MIA-injection) that evoked responses of
spinal neurones are facilitated and significantly corre-
lated with pain behaviour [10], implicating a contribu-
tion of central sensitization to aberrant pain responses
at these later stages. The presence of distal allodynia in
Figure 5 Nimesulide attenuates microglia and astrocyte
activation in MIA-treated rats. A: Repeated administration of
nimesulide (10 mg.kg-1; days 14-20) significantly attenuated MIA-
induced increases in Iba-1 positive activated microglia in the
ipsilateral dorsal horn on day 21 and day 28, compared to vehicle-
treated rats. B: Repeated administration of nimesulide (10 mg.kg-1;
days 14-20) did not alter GFAP immunofluorescence on day 21.
Nimesulide treatment did, however, significantly attenuate MIA-
induced increases in GFAP immunofluorescence in the ipsilateral
dorsal horn at day 28, compared to vehicle-treated rats. Data are
expressed as mean ± SEM. Statistical analyses comparing effects of
nimesulide treatment versus vehicle were performed using a 1 way
ANOVA with a Bonferroni post hoc test: *p < 0.05, **p < 0.01. ***p
< 0.001.
Figure 6 Minocycline attenuates microglia and astrocyte activation in MIA-treated rats. A: Minocycline treatment (30 mg.kg-1) significantly
attenuated MIA-induced increases in Iba-1 positive activated microglia in the ipsilateral dorsal horn at day 28, compared to the effects of vehicle
treatment in MIA-injected rats. B: Minocycline treatment (30 mg.kg-1) significantly attenuated MIA-induced increases in GFAP
immunofluorescence in the ipsilateral dorsal horn at day 28, compared to MIA-treated rats which received vehicle. Data are expressed as mean ±
SEM. Statistical analyses comparing effects of minocycline treatment versus vehicle were performed using a Student’s t test: **p < 0.01. ***p <
0.001.
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the MIA model may reflect the presence of nerve
damage, as previously described [20], changes in the
receptor expression in peripheral nerves innervating the
joint [24], and a potential role of infiltrating immune
cells and satellite glia [17], all of which may contribute
to the increase spinal excitability seen in this model.
Spinal COX-2 expression plays a crucial role in central
sensitization in models of pain [25,26]; the increase in
spinal COX-1 and COX-2 mRNA in MIA-treated rats
[27] supports a contribution of central sensitization to
OA pain. Our current work further advances this
hypothesis through the demonstration of a time-depen-
dent activation of microglia and astrocytes in the spinal
cord in this model of OA pain.
The activation of microglia and astrocytes in the
spinal cord has been widely reported in different models
of chronic pain, and their contribution to pro-inflamma-
tory spinal mechanisms of central sensitization has been
described [see references in [12]]. The presence of acti-
vated microglia and astrocytes in the spinal cord in this
model of OA pain suggests these cells may also contri-
bute to the associated pain behaviour. In models of neu-
ropathic pain, microglia are activated in the spinal cord
at earlier timepoints compared to astrocytes [see refer-
ences in [28]]. This temporal profile, plus the evidence
from pharmacological studies using minocycline, sup-
port the notion that microglia have a prominent role in
the development, but not the maintenance, of hyperalge-
sia and allodynia in models of neuropathic pain [19].
Thus, the early activation of microglia followed by the
later activation of astrocytes that we describe in the
MIA model of OA pain is consistent with that reported
in neuropathic pain states [16,19,29] and the report that
microglia activation is associated with all phases of
inflammation whereas astrocyte activation is only
observed during subacute and chronic phases of inflam-
mation [30]. These data suggest there is a neuronal-glial
cascade of activation which is common to different
models of chronic pain. In this regard it is noteworthy
that the presence of activated microglia and astrocytes
in the MIA-model was observed at later timepoints than
that reported for models of neuropathic and inflamma-
tory pain, this slower onset may reflect the development
of structural changes within the joint.
Microglia are activated in response to numerous cues,
many of which can be released from primary sensory
afferents [17,31]. Although distal allodynia and activa-
tion of spinal microglia was evident from day 7 post-
MIA injection, it was only at day 28 that levels of acti-
vated microglia were significantly correlated with distal
allodynia. Consistent with the profile of glial cell activa-
tion in other models of chronic pain, GFAP immuno-
fluorescence was only significantly increased at day 28,
at which timepoint GFAP immunofluorescence was also
significantly correlated with distal allodynia. The activa-
tion of spinal astrocytes coincides with the facilitation of
evoked responses of spinal neurones and the significant
correlation of distal allodynia with cartilage and bone
pathology previously reported [10].
To assess the potential contribution of the activated
microglia and astrocytes to the MIA-induced pain beha-
viour, we evaluated the effects of two different classes of
drug, the COX inhibitor nimesulide [32,33] and the tet-
racycline minocycline [19], on pain responses. Treat-
ment with both of these drugs attenuated both pain
behaviour and the activation of microglia and astrocytes
in the spinal cord in this model of OA pain. Previously,
nimesulide has been shown to attenuate microglia acti-
vation in models of neuroinflammation [32,33], which is
likely to be an indirect effect as a result of COX inhibi-
tion [34]. Minocycline has well-described effects on
microglia activation [see refs in 19], however there are
also reports that minocycline can have direct effects on
dorsal root ganglia neurones [35] and the trafficking of
immune cells into the dorsal root ganglia [36], both of
which may contribute to the effects reported herein.
Our data support the recent report that pain beha-
viour is associated with the activation of spinal microglia
at earlier timepoints in this model of OA pain [22] and
advance our understanding of the contribution of glial
cells, to include a role of astrocytes, at later stages in
this model of OA pain. Repeated dosing with nimesulide
(day 14-20) significantly decreased pain behaviour and
the number of activated microglia in the ipsilateral
spinal cord of MIA-treated rats as assessed at day 21
post MIA-injection. At this timepoint, GFAP immuno-
fluorescence in the spinal cord was not altered in MIA-
treated rats per se, and nimesulide treatment had no
effect on this marker of astrocyte activation. Given the
robust effects of nimesulide on pain behaviour and
microglia activation, it was of interest to determine
whether the inhibitory effects of nimesulide had any sus-
tained effects on pain behaviour and glial cell activation.
Following cessation of drug treatment, changes in
weight bearing on the MIA-injected joint returned to
pre-nimesulide values, by contrast there was a sustained
inhibition of distal allodynia and levels of activated
microglia and astrocytes at day 28. Given that nimesu-
lide is cleared within 40 h post-drug administration in
the rat [34], the sustained effects of nimesulide are likely
to arise from the modulation of pain mechanisms rather
than residual drug action. The dissociation between the
effects of nimesulide on the two pain behaviours once
drug treatment has ceased, suggests that changes in
weight bearing and distal allodynia are mediated by dif-
ferent mechanisms at this later timepoint in MIA-trea-
ted rats. Alterations in spinal glial glutamate transport
are implicated as one of the underlying mechanisms of
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allodynia in other models of chronic pain, and inhibition
of astrocyte activation with propentofylline modulates
both pain behaviour and glial glutamate promoter acti-
vation [37]. Whether similar mechanisms contribute to
the chronic pain responses seen in the MIA model, and
the sustained effects of nimesulide on mechanical allo-
dynia, compared to weight bearing described herein,
remain to be determined.
Our pharmacological data support an important con-
tribution of activated spinal microglia and astrocytes to
distal allodynia at later timepoints in this model. Indeed,
the lack of effect of nimesulide treatment on joint
pathology suggests peripheral effects are unlikely to
overtly contribute to the inhibitory effects of nimesulide
on pain behaviour. It is of particular note that although
astrocytes are quiescent during the period over which
nimesulide treatment was administered (14-20 days) in
the MIA-treated rats, this treatment did attenuate the
later activation of astrocytes at day 28. The role of
microglia signalling to astrocytes and their subsequent
activation is well established [38-40], thus it is feasible
that the effects of nimesulide on astrocyte activation
arise as a result of the inhibition of microglia activation
during the earlier stages of the model.
In conclusion, the present study has demonstrated the
presence of activated microglia and astrocytes in the
spinal cord in the MIA model of OA pain. The signifi-
cant correlation between distal allodynia and activation
of spinal glial cells, plus the attenuation of pain beha-
viour by inhibitors of glial cell activation, provides the
first evidence that both spinal microglia and astrocytes
contribute to behavioural pain responses in this model
of OA pain. The association of astrocytes with aberrant
pain behaviour was only evident at later time-points,
which corresponds to the manifestation of spinal neuro-
nal facilitation in this model [10]. Our preclinical data
support recent clinical evidence that OA pain is accom-
panied with central sensitization [4] and implicate a
contribution of activated glial cells to these chronic pain
mechanisms.
Methods
Rats were purchased from Charles River U.K. All studies
were carried out in accordance with UK Home Office
Animals (Scientific Procedures) Act (1986) and follow
the guidelines of the International Association for the
Study of Pain. A total of 91 male Sprague Dawley rats
weighing 160-190 g were used for these studies (n = 32
rats for behavioural pharmacology studies, n = 59 rats
for immunohistochemical studies).
Intra-articular injections and behavioural testing
Adult male Sprague Dawley rats (160-190 g) were
anesthetised with isoflurane (1.5-2% in 50% N2O-50%
O2) and received a single intra-articular injection of
monosodium iodoacetate (MIA; 1 mg/50 μl; Sigma U.K.)
in saline through the infra-patellar ligament of the left
knee. The dose of MIA was based on the previous lit-
erature [5,41,42]. Control animals received a single
intra-articular injection of saline (50 μl).
Baseline behavioural measurements were taken prior
to intra-articular injection (postoperative day (PO) 0)
and then from PO day 7 onwards. Effects of MIA or sal-
ine injection on weight-distribution through the left
(ipsilateral) and right (contralateral) knee were assessed
using an incapacitance tester (Linton Instrumentation,
U.K.) between post-operative days 7-28. Hind-paws were
placed on separate sensors and the force (in grams)
exerted by each hind limb was calculated and averaged
over a period of 3 seconds as previously described
[43,44]. Each data point was taken as the mean of three
3 sec readings. The development of mechanical allody-
nia was assessed using von Frey monofilaments
(Semmes-Weinstein monofilaments of bending forces 1,
1.4, 2, 4, 6, 8, 10 and 15 g) as previously described [10].
Von Frey monofilaments were applied to the plantar
surface of both hind-paws for a 3 sec period. Once a
withdrawal reflex was established, the paw was retested
with the next descending von Frey monofilament until
no response occurred. The lowest weight of monofila-
ment which elicited a withdrawal reflex was noted as
the paw withdrawal threshold (PWT).
Drug treatment
The effects of repeated (day 14-21 post MIA-injection)
oral administration of nimesulide (10 mg.kg-1; Tocris,
U.K.; n = 8 rats per group), or vehicle (2% methylcellu-
lose in distilled water; n = 8 rats per group), on changes
in weight bearing and mechanical allodynia were
assessed for 7 days in MIA and saline-treated rats.
Weight bearing and mechanical allodynia were assessed
before nimesulide administration and at 40 min intervals
post-drug administration. To determine whether there
were any longer-term effects of repeated dosing with
nimesulide on pain behaviour, which outlast the dosing
schedule, behavioural testing was continued from days
21-28. At day 28 rats were killed and spinal cord and
joints were collected for gene expression studies and
joint histology, respectively. In a separate group of rats,
the effects of the nimesulide treatment on the numbers
of activated microglia and astrocytic activation in the
spinal cord of MIA- and saline-treated rats were deter-
mined (n = 5 rats per group). Rats were perfused at
days 21 or day 28 post-MIA injection and spinal cords
were removed and prepared for immunohistochemistry
(see below). In a final series of experiments, the effects
of another glial cell inhibitor minocycline (30 mg.kg-1
daily treatment from day 14-28) on pain behaviour (as
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described above) was determined in MIA-treated rats.
At day 28 post MIA-injection, rats were perfused and
spinal cords were collected for immunohistochemical
analysis.
Immunohistochemistry
Rats were overdosed with sodium pentobarbital and
transcardially perfused with saline (0.9%) followed by 4%
paraformaldehyde (PFA; Sigma, U.K). The lumbar spinal
cord was removed, post-fixed (4% PFA for 4 h) and
stored in 30% sucrose in 0.1 M phosphate buffer/0.02%
sodium azide solution at 4 C. Immunohistochemical
staining was performed on 40 μm free-floating cryosec-
tions of L3/L4/L5 spinal cord (n = 4-6 rats per group,
5-6 individual spinal sections per animal). Microglial
cells were stained using Iba-1 [45] and astrocytes were
stained using GFAP [46]. Sections were blocked for 1 hr
in 0.1 M phosphate buffer saline containing 3% normal
goat serum and 0.3% Triton X-100 at room tempera-
ture. Sections were then incubated at 4°C for 72 h with
rabbit a-Iba-1 (Wako, Japan) diluted 1:1000 in Trizma
Triton X-100 buffered saline (TTBS) or incubated at
room temperature 20-22°C for 18 h with mouse anti-
GFAP (Thermo-Fisher, Leicestershire, UK) diluted 1:100
in TTBS Five 10 min washes in 0.1 M phosphate buffer
(PB) were carried out between all subsequent steps. Sec-
tions were incubated for 2 h at room temperature with
Alexafluor 488 conjugated goat a-rabbit secondary anti-
body (Molecular probes, Oregon) diluted 1:300 in TTBS
(for Iba-1) or with Alexafluor 568 conjugated goat a-
mouse secondary antibody (Molecular probes, Oregon)
diluted 1:300 in TTBS (for GFAP). Sections were then
mounted on gelatinized microscope slides, air-dried
overnight at room temperature in the dark and cover-
slipped using Fluromount (Sigma).
Quantification of glial activation
Iba-1 immunostaining was visualised using a 20 × 0.4
NA objective lens on a Leica DMIRE2 fluorescence
microscope, running Volocity 5.5 (PerkinElmer)
equipped with a Hamamatsu Orca C4642-95 camera.
Images were acquired using a typical exposure time of
750 ms. Total numbers of positively identified activated
microglia expressing Iba-1 were counted manually in
both ipsi- and contralateral quadrants of individual sec-
tions (Additional file 4, Figure S4). Microglia were
defined as activated if they displayed a clearly swollen
cell body with reduced processes, these differ from nor-
mal or resting microglia where cell bodies are largely
absent and large ramified processes are displayed.
Assessment was performed by two independent blinded
investigators, who quantified total number of activated
microglia. For further analysis (Figure 1), numbers of
activated microglia on the ipsilateral side were expressed
as a percentage of the number on the contralateral side.
Images for astrocyte (GFAP) grey intensity calculation
were produced via capture on a Leica DMRB fluores-
cence microscope using a 40X 1.25NA oil immersion
objective lens Images were acquired using Openlab (Per-
kinElmer) to control a Hamamamtsu Orca C4642-95
camera. For quantification of GFAP, single-plane images
of the superficial dorsal horn of the spinal cord were
acquired on the pre-described system using an identical
exposure time of 100 ms. Background fluorescence was
measured by taking an image of an area within the sam-
ple, using the parameters described above, which con-
tained no labelled structures that was then subtracted
from all images using IMAGE J (NIH open software
with Macbiophotonics plugins). Following background
subtraction, mean fluorescence grey intensity was deter-
mined for each image using IMAGE J. All image analy-
sis, cell counts and fluorescence measurements were
performed “off-line” on captured images taken from
stained sections. All and counts were independently ver-
ified by a second experimentor.
RNA extraction and cDNA synthesis
Ipsilateral and contralateral spinal cord samples were
dissected from MIA and saline-treated rats (n = 8 rats
per group) and were frozen. Samples were homoge-
nized in 2 ml of ice cold Tri reagent (Sigma-Aldrich,
UK) and RNA purified according to the manufacturers’
instructions. For cDNA synthesis, 100 ng of total RNA
was reverse transcribed using M-MLV reverse tran-
scriptase (Invitrogen) in a total reaction volume of
20 μl, as per the manufacturers’ instructions. Reactions
were incubated for 10 min at 25°C, 50 min at 37°C
and the reaction terminated by incubation at 70°C for
15 min.
Taqman quantitative real time polymerase chain reaction
Gene expression was quantified utilising the relative
standard curve method, based on Taqman quantitative
real time polymerase chain reaction (qRT-PCR), as pre-
viously described [47]. Primers and probes were
obtained from published work (GFAP - [48], b-actin -
[49]), and synthesised by MWG Biotech, (Germany).
Data are expressed as a ratio of gene expression levels
with reference to b-actin. GFAP forward primer - 5-
TGGCCACCAGTAACATGCAA-3, reverse primer - 5-
CAGTTGGCGGCGATAGTCAT-3, Taqman probe - 5-
CAGACGTTGCTTCCCGCAACGC-3. Β-actin forward
primer - 5- AGGCCATGTACGTAGCCATCCA-3,
reverse primer - 5- TCTCCGGAGTCCATCACAATG-
3, Taqman probe - 5- TGTCCCTGTATGCCTCTGG
TCGTACCAC -3.
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Histology
Joint histology was conducted as previously described
[10]. MIA- and saline-treated joints (day 28) were fixed
in 10% formal saline and decalcified in an aqueous ethy-
lenediaminetetraacetic acid (EDTA) solution (14% in
distilled water; pH 7.0, 20°C). Samples were paraffin
embedded and 5-8 μM sections of the central portion of
the knee joint, in the coronal plane, were stained by
safranin-O fast green to show matrix proteoglycan and
overall joint morphology. Medial and lateral knee com-
partment tibial plateaux cartilage, tibial subchondral
bone and joint synovium were scored as previously
described [10].
Statistical Analyses
Statistical analyses comparing effects of MIA-treatment
versus saline-treatment on weight-bearing and paw
withdrawal thresholds were carried out using a 2-way
ANOVA with a Bonferroni post hoc test. Statistical ana-
lyses comparing effects between treatment groups
(nimesulide-treated versus vehicle-treated on weight
bearing and paw withdrawal thresholds) were performed
using a Kruskall-Wallis test with a Dunn’s post hoc test
and area under the curve analysis with a Mann Whitney
test. Statistical analyses comparing the effect of minocy-
cline versus vehicle on pain behaviour at day 28 post
MIA-injection was performed using a Student’s unpaired
t Test. Statistical analyses of GFAP intensity used either
a one-way or two-way ANOVA (as listed in figure
legends) with a Bonferroni post hoc test. Statistical ana-
lyses of changes in number of activated microglia in the
spinal dorsal horn of MIA versus saline-treated rats
were performed using a Kruskall Wallis test with a
Dunn’s post hoc test. Statistical analysis of gene expres-
sion studies was performed using a Student’s unpaired t
Test. Correlations were performed using the 2-tailed
Spearman’s rank correlation.
Additional material
Additional file 1: Figure S1: MIA-induced pain behaviour. Intra-
articular injection of MIA (1 mg/50 μl) produced significant decreases in
(A) weight bearing on ipsilateral hind paw and (B) hindpaw mechanical
withdrawal thresholds in the ipsilateral limb of rats compared to saline-
treated rats. Data are expressed as mean ± SEM. Statistical analyses
comparing MIA and saline-treated rats were performed using a two way
ANOVA with a Bonferroni post hoc test, ***p < 0.001.
Additional file 2: Figure S2: Positively identified spinal microglia
and GFAP immunofluorescence in the saline-treated rats. A:
Positively identified spinal microglia in the ipsilateral and contralateral
spinal cord of saline-treated rats at day 28. B: GFAP immunofluorescence
in the ipsilateral and contralateral spinal cord of saline-treated rats at day
28.
Additional file 3: Figure S3: Spinal GFAP gene expression in MIA-
treated rats. GFAP mRNA in the ipsilateral and contralateral spinal cord
of saline and MIA-treated rats at day 28. Data are normalised to levels of
b-actin and expressed as mean ± SEM. Statistical comparison between
MIA and saline-treated rats was performed using a Student’s unpaired t
test.
Additional file 4: Figure S4: Schematic of the areas of spinal cord
used for quantification. Lumbar sections 3-5 of the spinal cord, red box
(illustrates the area of analysis for Iba-1) and the blue box (illustrates the
area of analysis for GFAP). Note images were captured from both sides
of the spinal cord for microglia and astrocytes. Adapted from: Molander,
C. and Grant, G., 1995, spinal cord cytoarchitecture. In G. Paxinoa (Ed),
The Nervous System, Second Edition, Academic Press, San Diego.
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